DongKookPharmaceutical

At a glance

DongKookPharmaceutical filed 17 disclosures in the last 12 months, including 1 5% holder and 1 buyback. The most recent key filing was on May 26.

Revenue for 2025 was ₩927B, up 14.1% on 2024. Operating margin was 10.4% against 9.9% a year earlier. Debt was 39% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩510B and operating profit of ₩53.4B.

The 2025 annual report lists 1,306 employees with an average tenure of 6.1 years and average pay of ₩67.6M, #663 of 1,829 listed companies by average pay. Its 4 directors and auditors were paid ₩364M each on average. It paid ₩200 per common share in cash dividends, against ₩200 a year earlier (+0%). 동국헬스케어홀딩스(주) and related parties held 44.23% at year end.

From the 2025 annual report

Staff: 1,306 (831 men, 475 women), of whom 62 on fixed-term contracts. Total pay for the year: ₩88.7B. Directors and auditors: 4, paid ₩1.5B in total.

Dividends (common shares)

Largest shareholder

동국헬스케어홀딩스(주) holds 20.62%; with 7 related parties the group holds 44.23% of common shares at year end (from 44.19% at the start of the year).

Individuals paid ₩500M or more

Auditor: 삼정회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary